Pastick Katelyn A, Okafor Elizabeth C, Wang Fan, Lofgren Sarah M, Skipper Caleb P, Nicol Melanie R, Pullen Matthew F, Rajasingham Radha, McDonald Emily G, Lee Todd C, Schwartz Ilan S, Kelly Lauren E, Lother Sylvain A, Mitjà Oriol, Letang Emili, Abassi Mahsa, Boulware David R
Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota.
Open Forum Infect Dis. 2020 Apr 15;7(4):ofaa130. doi: 10.1093/ofid/ofaa130. eCollection 2020 Apr.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine have garnered unprecedented attention as potential therapeutic agents against COVID-19 following several small clinical trials, uncontrolled case series, and public figure endorsements. While there is a growing body of scientific data, there is also concern for harm, particularly QTc prolongation and cardiac arrhythmias. Here, we perform a rapid narrative review and discuss the strengths and limitations of existing and clinical studies. We call for additional randomized controlled trial evidence prior to the widespread incorporation of hydroxychloroquine and chloroquine into national and international treatment guidelines.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)是一种迅速出现的病毒感染,可导致2019冠状病毒病(COVID-19)。在几项小型临床试验、非对照病例系列研究以及公众人物的支持下,羟氯喹和氯喹作为对抗COVID-19的潜在治疗药物受到了前所未有的关注。虽然科学数据越来越多,但也有人担心其危害,尤其是QTc延长和心律失常。在此,我们进行了一项快速叙述性综述,并讨论了现有研究和临床研究的优势与局限性。我们呼吁在将羟氯喹和氯喹广泛纳入国家和国际治疗指南之前,获得更多随机对照试验的证据。